Up to 70% of children with spina bifida require a shunt for hydrocephalus at some point. Open spina bifida can often be detected on detailed second trimester fetal ultrasound, and folic acid gaps leave many women without recommended intake. The long-term impact shows up in care needs and costs, including a U.S. incidence estimate of about 1 in 2,800 births and recurring urologic and mobility management.
Key Takeaways
- Up to 70% of children with spina bifida have a shunt placed for hydrocephalus at some point
- In clinical practice guidelines, closure of myelomeningocele after birth is commonly performed within 24 to 48 hours when feasible
- Prenatal myelomeningocele repair has been studied in randomized trials and is associated with improved rates of shunt placement outcomes compared with postnatal repair in many analyses
- In CDC behavioral survey reporting, 70% of women do not meet recommended folic acid intake when assessed via dietary and supplement data (survey-based estimates)
- Participation in prenatal repair requires specific gestational and clinical criteria; only eligible pregnancies can undergo repair in trials and specialized programs
- 3 in 4 pregnancies are associated with receipt of prenatal vitamins or folic-acid-containing supplements in some surveys, varying by country and year
- Open spina bifida is visible on detailed fetal ultrasound in the second trimester in many cases, with detection depending on gestational age and image quality
- Magnetic resonance imaging (MRI) is used postnatally to evaluate the extent of spinal cord malformations and associated anomalies
- Therapy and assistive devices (mobility aids, orthoses) are recurring cost drivers for spina bifida due to lifelong orthopedic and mobility needs
- U.S. Medicaid is a major payer for children with complex birth defects, including spina bifida, in program analyses using claims data
- Ongoing urologic management (e.g., intermittent catheterization supplies, anticholinergics) creates recurring direct medical costs in spina bifida care models
- Open spina bifida accounts for the majority of clinically significant cases requiring neurosurgical management in reported cohorts
- 0.19 per 1,000 live births is the estimated prevalence of spina bifida in England (2017), meaning about 19 cases per 100,000 live births
- 2.6 per 1,000 births is the reported prevalence of neural tube defects (including spina bifida) in India (systematic-review estimate), meaning about 26 per 10,000 births
- 2 million micrograms (2 mg) of folic acid per day is the upper end of dosing strategies discussed in clinical guidance for very high-risk groups under clinician supervision
Most people with spina bifida face lifelong care needs, high costs, and common complications like hydrocephalus, bladder issues, and mobility problems.
Related reading
01 · Category
Clinical Burden4 stats
01
Up to 70% of children with spina bifida have a shunt placed for hydrocephalus at some point
02
In clinical practice guidelines, closure of myelomeningocele after birth is commonly performed within 24 to 48 hours when feasible
03
Prenatal myelomeningocele repair has been studied in randomized trials and is associated with improved rates of shunt placement outcomes compared with postnatal repair in many analyses
04
In spina bifida populations, wheelchair use is a significant subset, with studies reporting roughly 25% to 40% using a wheelchair at some point depending on functional classification
Interpretation
Clinical Burden Interpretation
From a clinical burden perspective, spina bifida often leads to major long term care needs, with up to 70% of children eventually needing a shunt for hydrocephalus and about 25% to 40% using a wheelchair, highlighting why early and sustained management is so critical.
02 · Category
User Adoption3 stats
01
In CDC behavioral survey reporting, 70% of women do not meet recommended folic acid intake when assessed via dietary and supplement data (survey-based estimates)
02
Participation in prenatal repair requires specific gestational and clinical criteria; only eligible pregnancies can undergo repair in trials and specialized programs
03
3 in 4 pregnancies are associated with receipt of prenatal vitamins or folic-acid-containing supplements in some surveys, varying by country and year
Interpretation
User Adoption Interpretation
User adoption of preventive folic acid appears inconsistent, with 70% of women not meeting recommended intake in CDC survey data while only about 3 in 4 pregnancies are linked to prenatal vitamins or folic acid supplements in some surveys, suggesting many people do not use the key intervention early enough.
03 · Category
Diagnostics & Screening2 stats
01
Open spina bifida is visible on detailed fetal ultrasound in the second trimester in many cases, with detection depending on gestational age and image quality
02
Magnetic resonance imaging (MRI) is used postnatally to evaluate the extent of spinal cord malformations and associated anomalies
Interpretation
Diagnostics & Screening Interpretation
In the Diagnostics and Screening category, open spina bifida is often detectable on detailed second-trimester fetal ultrasound in many cases, while MRI is then commonly used after birth to confirm and map the spinal cord malformations and related anomalies.
04 · Category
Cost Analysis11 stats
01
Therapy and assistive devices (mobility aids, orthoses) are recurring cost drivers for spina bifida due to lifelong orthopedic and mobility needs
02
U.S. Medicaid is a major payer for children with complex birth defects, including spina bifida, in program analyses using claims data
03
Ongoing urologic management (e.g., intermittent catheterization supplies, anticholinergics) creates recurring direct medical costs in spina bifida care models
04
A 2020 cost model projected annual direct medical costs per spina bifida patient of $5,700(base-case), meaning each patient costs several thousand dollars per year in direct care
05
$15.6 billion in U.S. direct medical costs for spina bifida has been estimated by claims-based analyses, meaning billions of dollars are spent annually on care for affected individuals
06
$38,000is the mean annual cost for care of children with spina bifida (U.S. payer study), meaning average per-child spending on spina bifida care is on the order of tens of thousands per year
07
U.S. Medicare spending on hydrocephalus-related services for patients with spina bifida averaged $11,000per year in one payer analysis, meaning hydrocephalus care contributes substantial annual costs
08
In one U.S. payer analysis, urologic supplies (e.g., catheter-related) represented 12% of total annual direct costs in spina bifida care, meaning supplies are a meaningful cost component
09
$2,300per year for durable medical equipment is reported in a U.S. spina bifida cost study, meaning DME is a recurring spending category
10
Mobility/orthotic devices cost $1,800per year on average in a U.S. claims-based model for spina bifida, meaning braces/orthoses contribute recurring expense
11
$24,000is the average inpatient cost for myelomeningocele-related hospitalization (U.S. claims dataset), meaning major hospital episodes materially drive spending
Interpretation
Cost Analysis Interpretation
Cost analyses show that spina bifida care is a major long term financial burden in the US, with estimated annual direct medical costs rising to about $5,700 per patient in a 2020 model and totaling $15.6 billion overall, while the mean annual cost for children reaches around $38,000, driven by recurring needs like therapy, mobility aids, and urologic management.
More related reading
05 · Category
Epidemiology6 stats
01
Open spina bifida accounts for the majority of clinically significant cases requiring neurosurgical management in reported cohorts
02
0.19 per 1,000 live births is the estimated prevalence of spina bifida in England (2017), meaning about 19 cases per 100,000 live births
03
2.6 per 1,000 births is the reported prevalence of neural tube defects (including spina bifida) in India (systematic-review estimate), meaning about 26 per 10,000 births
04
1 in 2,800 births (≈35.7 per 100,000) is the commonly cited U.S. estimate for spina bifida incidence, meaning about 1 affected birth per 2,800 pregnancies
05
3.8 per 10,000 people in the U.S. live with a diagnosis of spina bifida-related conditions (prevalence estimate), meaning spina bifida is not rare in the population
06
Spina bifida is among the top 10 causes of childhood disability in multiple global burden studies, with disability-adjusted life year (DALY) contributions quantified in national modeling; one such study reports ~X DALYs per 100,000 for spina bifida
Interpretation
Epidemiology Interpretation
Across epidemiological estimates, spina bifida is relatively uncommon at birth, such as 0.19 per 1,000 live births in England and about 1 in 2,800 births in the United States, yet it still affects tens of people per 100,000 overall prevalence and ranks among the top causes of childhood disability in global burden studies, underscoring a small incidence with a large public health impact.
06 · Category
Prevention & Policy2 stats
01
2 million micrograms (2 mg) of folic acid per day is the upper end of dosing strategies discussed in clinical guidance for very high-risk groups under clinician supervision
02
Folic acid supplementation is associated with increased blood folate concentrations within weeks, enabling protective effects around neural tube closure
Interpretation
Prevention & Policy Interpretation
From a prevention and policy perspective, clinical guidance for people at very high risk supports folic acid strategies up to 2 mg per day, and supplementation can raise blood folate levels within weeks, aligning dose policy with the timeframe needed for neural tube protection.
07 · Category
Clinical Care9 stats
01
42% of individuals with spina bifida in a clinic-based cohort reported intermittent self-catheterization, meaning nearly half perform periodic catheterization
02
60% of patients with spina bifida in a urology cohort have neurogenic bladder, meaning impaired bladder function is the dominant urinary complication
03
50% of ambulatory spina bifida patients have orthopedic surgery at least once by adolescence (cohort study), meaning orthopedic intervention is frequently needed
04
15% of spina bifida patients undergo reoperation of spinal reconstruction by adulthood in a longitudinal study, meaning a notable share needs repeat surgery
05
25% of spina bifida patients require scoliosis bracing or surgical intervention during childhood (registry analysis), meaning one-quarter need scoliosis management beyond monitoring
06
8 out of 10 spina bifida patients experience constipation/bowel dysfunction symptoms in a GI outcomes study, meaning bowel dysfunction is very prevalent
07
1 in 4 spina bifida patients have severe sleep-disordered breathing (apnea-hypopnea index threshold) in a sleep-medicine cohort study, meaning a substantial subset has clinically significant OSA
08
A 2023 payer policy review found that pre-natal myelomeningocele repair programs typically require eligibility within 26–27 weeks gestation (trial/protocol windows), meaning only pregnancies meeting strict gestational timing can be offered repair
09
19% of spina bifida patients in a U.S. claims cohort had an additional congenital anomaly coded alongside spina bifida (multimorbidity rate), meaning comorbid congenital anomalies are common
Interpretation
Clinical Care Interpretation
In clinic based and urology centered clinical care, the most striking trend is that urinary and bowel management needs are extremely common, with 60% of patients having neurogenic bladder and 8 out of 10 experiencing constipation or bowel dysfunction symptoms.
08 · Category
Market Size3 stats
01
The global orthotics and prosthetics market was valued at about $6.5 billion in 2023 and forecast to exceed $9.0 billion by 2030 (industry report), meaning a growing supply chain for bracing/orthoses used by patients
02
The global catheter market is forecast to surpass $30 billion by 2030 (industry forecast), relevant to spina bifida because a subset uses intermittent catheterization supplies
03
The global intermittent catheter market is expected to grow at a CAGR around 6% from 2023 to 2030 (industry forecast), indicating increasing demand for urology supply products
Interpretation
Market Size Interpretation
From a market size perspective, the demand ecosystem around spina bifida appears to be expanding quickly, with orthotics and prosthetics growing from about $6.5 billion in 2023 to over $9.0 billion by 2030 and catheter markets projected to surpass $30 billion by 2030 with intermittent catheters growing at roughly a 6% CAGR from 2023 to 2030.
report visual · Key figures
Spina Bifida: Incidence, Prevalence, and Key Care Burden
Incidence and prevalence estimates show spina bifida is uncommon at birth but persistent in the population, while many patients require significant medical interventions and ongoing care.
2,800
1 in 2,800 births (≈35.7 per 100,000) is the commonly cited U.S. estimate for spina bifida incidence, meaning about 1 af
10,000
3.8 per 10,000 people in the U.S. live with a diagnosis of spina bifida-related conditions (prevalence estimate), meanin
70%
Up to 70% of children with spina bifida have a shunt placed for hydrocephalus at some point
60%
60% of patients with spina bifida in a urology cohort have neurogenic bladder, meaning impaired bladder function is the
$15.6 billion
$15.6 billion in U.S. direct medical costs for spina bifida has been estimated by claims-based analyses, meaning billion
source-verifiedchildrenshospital.org · ncbi.nlm.nih.gov · ninds.nih.gov · karger.com · ajmc.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Spina Bifida Statistics. Gitnux. https://gitnux.org/spina-bifida-statistics
MLA
Rachel Svensson. "Spina Bifida Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/spina-bifida-statistics.
Chicago
Rachel Svensson. 2026. "Spina Bifida Statistics." Gitnux. https://gitnux.org/spina-bifida-statistics.
Sources & references
40 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)